Skip to main content

Pain Associated With Fibromyalgia

3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Syneos Health
Syneos HealthNC - Morrisville
3 programs
3
DS-5565Phase 31 trial
DS-5565Phase 31 trial
DS-5565Phase 31 trial
Active Trials
NCT02187159Completed1,270Est. Jul 2016
NCT02187471Completed1,301Est. Jan 2017
NCT02146430Completed1,293Est. Jul 2016
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
3 programs
DS-5565PHASE_3
DS-5565PHASE_3
DS-5565PHASE_31 trial
Active Trials
NCT02234583Completed2,485Est. Apr 2017
Pfizer
PfizerNEW YORK, NY
1 program
PregabalinN/A
Viatris
ViatrisCANONSBURG, PA
1 program
PregabalinN/A1 trial
Active Trials
NCT01773993Completed534Est. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoDS-5565
Syneos HealthDS-5565
Syneos HealthDS-5565
Syneos HealthDS-5565
ViatrisPregabalin

Clinical Trials (5)

Total enrollment: 6,883 patients across 5 trials

NCT02234583Daiichi SankyoDS-5565

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Start: Feb 2015Est. completion: Apr 20172,485 patients
Phase 3Completed
NCT02187471Syneos HealthDS-5565

Treatment of Pain Associated With Fibromyalgia

Start: Jan 2015Est. completion: Jan 20171,301 patients
Phase 3Completed
NCT02187159Syneos HealthDS-5565

Treatment of Pain Associated With Fibromyalgia

Start: Nov 2014Est. completion: Jul 20161,270 patients
Phase 3Completed
NCT02146430Syneos HealthDS-5565

Treatment of Pain Associated With Fibromyalgia

Start: Oct 2014Est. completion: Jul 20161,293 patients
Phase 3Completed
NCT01773993ViatrisPregabalin

Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)

Start: Feb 2013Est. completion: Jul 2017534 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.